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Abstract. The long-acting somatostatin agonist octreotide can control TSH hypersecretion from most thyrotropic adenomas. Octreotide therapy has even been shown to improve chiasmal dysfunction. We report another patient in whom octreotide therapy was associated with gradual suppression of TSH hypersecretion, which escaped partially, dramatic and very rapid and sustained improvement of chiasm compression, and dramatic and sustained shrinkage of an unresectable TSH-secreting pituitary tumour. Unusual and prolonged gastrointestinal adverse reactions eventually disappeared except for steatorrhea. In conclusion, octreotide may be considered as first line treatment in patients with unresectable thyrotropic adenomas.
Native somatostatin has been shown to suppress tumour secretion from some primary thyrotropic adenomas (1, 2) .
The long-acting somatostatin analogue octreo¬ tide ) is effective in 70-80% of thyrotropinomas (3) (4) (5) (6) (7) ; moreover, as visual field de¬ fects have been reported to be improved in one patient (8) , this suggests that some degree of tumour shinkage may occur as in acromegalic pa¬ tients (9) (10) (11) (12) (Fig. 2, IA) . It filled the subfrontal subarachnoidal spaces and chiasmatic cistern (Fig. 2, IIA and IIIA) , and the optic chiasm was not distinguishable (Fig.   2, IIA (Fig. 2, IB) , the optic chiasm became visible (Fig. 2, IIB) , the subfrontal subarachnoidal and suprasellar spaces reappeared (Fig. 2, ÍIB (5) , whereas GH hypersécrétion is immediately suppressed in acromegaly (9, 10, 12) . TSH bioactivity was also inhib¬ ited, since FT3 levels dropped significantly in par¬ allel with TSH reduction. This was also the case in other patients treated with octreotide (3) (4) (5) , even when TSH was neither completely controlled (3) nor significantly reduced (3) . Octreotide therapy might even cause transient hypothyroidism (3, 4) . 
